Abstracts tagged "juvenile idiopathic arthritis-enthesitis (ERA) and tumor necrosis factor (TNF)"

Abstract Number: 1461 • 2015 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis
Emily Fox¹, Joyce Hsu², Elizabeth Chalom^3,4, Sarah Sertial⁵, KT Park⁶, Julia F Simard⁷, Pierre Quartier⁸, Maria Teresa Terreri⁹, Kevin Baszis¹⁰, Charlotte Borocco¹¹, Sampath Prahalad¹², Adam Reinhardt¹³, Dieneke Schonenberg¹⁴, Elizabeth D. Mellins¹⁵ and Devy Zisman¹⁶, ¹Pediatric Rheumatology, Stanford, Palo Alto, CA, ²Pediatric Rheumatology, Stanford University, Palo Alto, CA, ³Pediatrics, St Barnabas Med Center-ACC, Livingston, NJ, ⁴Pediatric Rheumatology, St. Barnabas Medical Center, West Orange, NJ, ⁵Children's Hospital of New Jersey, Livingston, NJ, ⁶Division of Gastroenterology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ⁸Hôpital Necker-Enfants Malades, Paris, France, ⁹Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ¹⁰Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ¹¹Necker Hospital for Sick Children, Paris, France, ¹²Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ¹³Faculty of Physicians of the University of Nebraska Medical Center, College of Medicine, Nebraska, NE, ¹⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ¹⁵Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA, ¹⁶Rheumatology Unit, Carmel Medical CenterThe Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease accompanied by systemic symptoms including lymphadenopathy, serositis, and hepatosplenomegaly. Recently, we encountered a patient previously…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].